| Autor: |
Tsui, Sze Pui, Tang, Tommy W.F., Ip, Ho-Wan, So, Jason Chi Chiu, Au, Chun Hang, Ma, Edmond S.K., Chan, Chris TL, Ng, Margaret, Cheng, Kelvin C K, Wong, Kit Fai, Siu, Lisa L.P., Yip, Sze Fai, Lin, Sy, Lau, Szeman June, Luk, T.H., Lee, Harold K K, Lau, Chi Kuen, Kho, Bonnie, Zhang, Chunxiao, Kwong, Yok Lam, Leung, Anskar Y.-H. |
| Zdroj: |
Blood; November 2018, Vol. 132 Issue: 1, Number 1 Supplement 1 p5267-5267, 1p |
| Abstrakt: |
Background. Acute myeloid leukaemia (AML) is a group of heterogeneous diseases with distinct clinicopathologic, cytogenetic and genetic features, sharing in common an abnormal increase in myeloblasts in blood or bone marrow (BM). Induction and consolidation chemotherapy as well as allogeneic haematopoietic stem cell transplantation (HSCT) are the mainstays of treatment. However, treatment outcome is unsatisfactory and only 30-40% patients achieve durable remission. Disease heterogeneity in AML may account for different treatment responses. In this study, we examined the mutation spectrum of cytogenetically normal AML (CN-AML) patients in Hong Kong, where AML treatment and indications for allogeneic HSCT are uniform, and evaluated their clinical outcome with respect to the specific gene mutations. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
